发现Palbociclib作为一种强大的c-Myc G4稳定剂用于肺癌治疗,使用分子对接,分子动力学模拟和体外活动评估
Jian Gao1, Chao Liang1, Jiacheng Yin2
1School of Medicine, Anhui University of Science and Technology, Huainan, China.
Molecular diversity
|January 21, 2024
概括
作为CDK4/6抑制剂的Palbociclib通过稳定c-Myc G4结构,有效抑制肺癌细胞的生长. 这种新的治疗方法在治疗由异常c-Myc活动驱动的癌症方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺癌仍然是全球癌症相关死亡的主要原因.
- 新的治疗策略对于改善患者的治疗结果至关重要.
- 针对c-Myc等致癌途径是癌症治疗的一个有希望的途径.
研究的目的:
- 调查CDK4/6抑制剂Palbociclib在抑制肺癌细胞增殖方面的疗效.
- 探索Palbociclib作为c-Myc G4稳定剂的潜力.
- 阐明Palbociclib抗癌作用背后的分子机制.
主要方法:
- 在H1299和A549肺癌细胞系中进行细胞活力测试 (IC50测定).
- 对c-Myc蛋白和mRNA表达水平的分析.
- 细胞周期分析和细胞亡试验.
- 循环二元化 (CD),分子对接和分子动力学 (MD) 模拟来评估G4结构稳定性和结合亲和力.
主要成果:
- 帕尔博西克利布显著抑制了肺癌细胞生长,IC50值为11.00微米 (H1299) 和11.74微米 (A549).
- 帕尔博西克利布治疗导致c-Myc蛋白和mRNA表达的降低.
- 药物诱导了细胞亡和G2/M细胞周期停止.
- CD,对接和MD模拟证实了Palbociclib能够稳定c-Myc G4结构并有效结合的能力.
结论:
- 帕尔博西克利布通过抑制增殖和诱导细胞死亡,对肺癌细胞表现出强大的抗癌活性.
- 帕尔博西克利布作为c-Myc G4稳定剂,提供了一种新的治疗机制.
- 这些发现支持Palbociclib作为针对异常c-Myc活性癌症的向治疗的潜力,需要进一步的临床研究.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
